TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28379623
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once-daily aspirin
Study: 28379623
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice-daily aspirin
Study: 28379623
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once-daily aspirin
Study: 28379623
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once-daily aspirin (control group)
Study: 28027636
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education group sessions (12 weekly 75-min sessions)
Study: 23273217
Drug: Multidisciplinary transmural
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multidisciplinary transmural rehabilitation programme (duration: 2 to 6 months) consisting of neurorehabilitation treatment, empowerment training, and stroke education.
Study: 31523022
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy during surgery
Study: 23415472
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin 20 IU BID for 3 weeks
Study: 23415472
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (in a small group of inpatients)
Study: 17154160
Drug: Saforis (glutamine)
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saforis (glutamine) powder, 3 times/day during Treatment Cycle 1
Study: 17154160
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 times/day during Treatment Cycle 1
Study: 15466766
Drug: Methotrexate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (10 mg) plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)
Study: 15466766
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)
Study: 15466766
Drug: Methotrexate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (10 mg) plus Prednisone
Study: 11244365
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (1 puff three times daily per nostril for 15 days)
Study: 861375
Drug: Total nodal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total nodal radiotherapy with combination chemotherapy
Study: 861375
Drug: Total nodal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total nodal radiotherapy without combination chemotherapy
Study: 25796966
Drug: Online Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Cognitive Behavior Therapy for Insomnia (CBTI)
Study: 19703236
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) combined with professional plaque control (PPC) (twice a week)
Study: 19703236
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) combined with chlorhexidine rinsing (CHX) (twice a day)
Study: 17902187
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injectable (RLAI) 25 mg every 14 days (60% of patients)
Study: 11595992
Drug: Chlorhexidine preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine preparation of skin before and during catheterization
Study: 28488021
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU only), N = 18
Study: 27241895
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 400mcg
Study: 16763748
Drug: 84 mg
Normalized name: silymarin 84 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84 mg soy isoflavones
Study: 16763748
Drug: 126 mg
Normalized name: glycerin 126 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 126 mg soy isoflavones
Study: 16763748
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg soy isoflavones)
Study: 1315211
Drug: WR-2721 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR-2721 plus radiation therapy (WR + RT)
Study: 1315211
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) only
Study: 3886724
Drug: Doxepin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (10 mg three times a day)
Study: 3886724
Drug: Diphenhydramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (25 mg three times a day)
Study: 30953892
Drug: Group Interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Interpersonal Psychotherapy (G‐IPT)
Study: 28202845
Drug: 2.50 g
Normalized name: IODINE 2.50 g in 1 L TOPICAL SOLUTION [QUARTER-BAC PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.50 g ALA-DAG
Study: 28202845
Drug: 1.25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g ALA-DAG
Study: 28202845
Drug: Control (0.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.00 g ALA-DAG)
Study: 23093337
Drug: Low-dose dietary
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dietary potassium alkali supplementation
Study: 23093337
Drug: High-dose dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dietary potassium alkali supplementation
Study: 18594001
Drug: 500 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m² pemetrexed (P500)
Study: 18594001
Drug: 1,000 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/m² pemetrexed (P1000)
Study: 17189542
Drug: Intravenous conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous conjugated estrogens (EST)
Study: 6322985
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (n = 15)
Study: 6322985
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to therapy (both groups)
Study: 31396667
Drug: Deep convolutional
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep convolutional neural network (CNN) with data augmentation, trained for 50 epochs, batch size of 8, learning rate of 0.0001, Adadelta optimizer, dropout of 0.20.
Study: 30611996
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (LF) administration for 3 months
Study: 19238219
Drug: Sulphadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine-pyrimethamine (SP) treatment in symptomatic children
Study: 19238219
Drug: Sulphadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine-pyrimethamine (SP) treatment in asymptomatic infants
Study: 19238219
Drug: Molecular markers
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular markers examination for drug resistance
Study: 15349013
Drug: Controlled-release paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release paroxetine (CR)
Study: 15349013
Drug: Immediate-release paroxetine
Normalized name: paroxetine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release paroxetine (IR)
Study: 11696462
Drug: sCD40L concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD40L concentration in cases (2.86 ng/mL)
Study: 11696462
Drug: sCD40L concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD40L concentration above 95th percentile (3.71 ng/mL)
Study: 9559206
Drug: Four serological
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four serological tests (Bio-Rad IgA, Bio-Rad IgG, Pyloriset EIA-A for IgA, Pyloriset EIA-G for IgG)
Study: 7870845
Drug: Apomorphine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.5 mg)
Study: 2975951
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Strategy (HDS) - interferon alpha‐N1 5M units m‐2 by continuous i.v. infusion over 24 h, escalating by 5 M units m‐2 day‐1 as tolerated over 10 days, repeated every 28 days.
Study: 2975951
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Strategy (LDS) - fixed dose of 2 M units m‐2 by intramuscular injection daily for 28 days, then daily for 7 days every other week.
Study: 31403361
Drug: Colchicine and
Normalized name: colchicine and probenecid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine and a single dose of Td vaccine
Study: 31403361
Drug: Placebo (colchicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (colchicine and a single dose of vitamin B6)
Study: 23103783
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium chloride injection (pain condition)
Study: 23103783
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection (sham condition)
Study: 23103783
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (control condition)
Study: 16849382
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine 2 mg/ml with fentanyl 2 microg/ml at 10 ml/h
Study: 16849382
Drug: Hourly boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hourly boluses of 10 ml of ropivacaine 2 mg/ml with fentanyl 2 microg/ml
Study: 16849382
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration
Study: 14519623
Drug: 7.5 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/m2/day rhAngiostatin
Study: 14519623
Drug: 15 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/m2/day rhAngiostatin
Study: 14519623
Drug: 30 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2/day rhAngiostatin
Study: 14519623
Drug: rhAngiostatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhAngiostatin treatment
Study: 9085397
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch plus brief physician counseling
Study: 8449586
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg daily
Study: 31655834
Drug: 4mg intramuscular
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg intramuscular dexamethasone immediately after anesthesia
Study: 23188075
Drug: Naltrexone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (0.1 mg/kg) orally for 8 weeks
Study: 14638544
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 6 weeks (Group 1)
Study: 1486386
Drug: Suby G
Normalized name: SUBY-G UROLOGICAL IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suby G washout
Study: 1486386
Drug: Solution R
Normalized name: SOLUTION ROLL-ON (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution R washout
Study: 6721446
Drug: Baclofen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (20 mg and 40 mg)
Study: 20082754
Drug: Yupingfeng Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yupingfeng Powder (10 days treatment)
Study: 16250192
Drug: ETMS use
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETMS use twice every weekday in 35‐min increments during an eight‐week period
Study: 12537632
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg twice a day for 3 days)
Study: 12537632
Drug: Vitamin B(1),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B(1), B(6) and B(12) tablets
Study: 9625319
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (1 g/day)
Study: 2467117
Drug: Amlodipine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (starting dose 2.5 mg, titrated to 5.0 mg and 10.0 mg at 2-week intervals)
Study: 2467117
Drug: Atenolol (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (starting dose 50 mg, titrated to 100 mg after 4 weeks)
Study: 26156818
Drug: Brenner's Integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brenner's Integrated Psychological Therapy (IPT) cognitive training, delivered once a week for 6 months
Study: 23870642
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron substitution (ferric carboxymaltose)
Study: 12576167
Drug: Levetiracetam with
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam with comedication not affecting drug metabolizing enzymes (gabapentin, lamotrigine, vigabatrin)
Study: 27502103
Drug: Bosentan 2
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 2 mg/kg, given by nasogastric tube twice daily for ≥48 hours and up to 1 day after iNO weaning.
Study: 27502103
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given by nasogastric tube twice daily for ≥48 hours and up to 1 day after iNO weaning.
Study: 20540635
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Probucol
Study: 17932160
Drug: Combined cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cardiac resynchronisation and implantable cardioverter defibrillator therapy
Study: 17932160
Drug: Implantable defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable defibrillator therapy
Study: 17932160
Drug: Resynchronisation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resynchronisation therapy alone
Study: 12095068
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (ALA) in combination with photodynamic therapy (PDT)
Study: 25056413
Drug: Ultrasonic scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaling followed by repeated antimicrobial photodynamic therapy (PDT)
Study: 22573244
Drug: Active rinse
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rinse with adjunct tongue scraping
Study: 15504872
Drug: Intrarectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal administration of quinine (16 or 20 mg/kg)
Study: 11679506
Drug: Pill users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill users
Study: 9477463
Drug: Centrifugal pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifugal pump with heparin-coated circuit (Group C)
Study: 3364308
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin B complex and vitamin C preparation
Study: 29178685
Drug: Multiple levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple levels of antidepressant treatment
Study: 21872708
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effect across sessions
Study: 15060899
Drug: Electrolytic iron
Normalized name: electrolytic iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrolytic iron (66 mg/kg)
Study: 15060899
Drug: Reduced iron
Normalized name: Reduced iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced iron (66 mg/kg)
Study: 8025741
Drug: ganciclovir 5
Normalized name: ganciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganciclovir 5 mg/kg once a day 5 d/wk (Group G)
Study: 8025741
Drug: acyclovir 800
Normalized name: acyclovir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acyclovir 800 mg four times a day (Group A)
Study: 2557572
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin 15,000 AXaU/day
Study: 2557572
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin 7,500 AXaU/day
Study: 2557572
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin 5000 I.U. t.i.d.
Study: 4548092
Drug: Standard endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard endocrine therapy
Study: 28062311
Drug: TRPA1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TRPA1 antagonist A-967079
Study: 28062311
Drug: TRPV1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRPV1 inhibitor BCTC
Study: 28062311
Drug: Amiloride (acid-sensing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (acid-sensing ion channel blocker)
Study: 28062311
Drug: pH 4.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH 4.3 continuous intraepidermal injection
Study: 21348897
Drug: Tumour infiltrating
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour infiltrating lymphocytes (TIL) treatment in 80 patients
Study: 16224198
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (375-3000 mg/day)
Study: 12964171
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg/d (60 mg b.i.d.)
Study: 12964171
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg/d (20 mg b.i.d.)
Study: 12964171
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg/d (40 mg b.i.d.)
Study: 12964171
Drug: Duloxetine >/=60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine >/=60 mg
Study: 9537485
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (NO) at 100 ppm
Study: 9537485
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (NO) at 640 ppm
Study: 9537485
Drug: No Inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Inhaled Nitric Oxide
Study: 843186
Drug: Immediate psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate psychotherapy treatment
Study: 31077425
Drug: Genotype-guided tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Genotype-guided tacrolimus doses (0.125 mg/kg/day for CYP3A5*1/*1, 0.1 mg/kg/day for *1/*3, 0.08 mg/kg/day for *3/*3)
Study: 31077425
Drug: Genotype-guided tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Genotype-guided tacrolimus doses
Study: 31077425
Drug: Conventional tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional tacrolimus doses (0.1 mg/kg/day)
Study: 27904905
Drug: Idarucizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (8 g as a 1-hour infusion)
Study: 27904905
Drug: Idarucizumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (4 g as a 5-minute infusion)
Study: 17251929
Drug: Native oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native oat bran with 11.6 g native beta-glucans
Study: 15364150
Drug: Improved treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved treatment reducing risk of restenosis and repeat revascularization
Study: 11272848
Drug: c‐SPHP 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: c‐SPHP 3 g per day
Study: 11272848
Drug: c‐SPHP 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: c‐SPHP 0 g per day (placebo)
Study: 2679864
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of elemental calcium per day
Study: 31507088
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel provided through family planning clinics (intervention clinics), n = 189
Study: 31507088
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel provided through CAPRISA research clinics (control clinics), n = 183
Study: 31507088
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel provided through family planning clinics (intervention clinics)
Study: 31507088
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel provided through CAPRISA research clinics (control clinics)
Study: 28963158
Drug: Povidone iodine-alcohol
Normalized name: isopropyl alcohol / povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone iodine-alcohol applied twice (PVI)
Study: 20624673
Drug: Isomalto-oligosaccharides (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomalto-oligosaccharides (IO) 10 g/d for 8 weeks
Study: 16478762
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine gel applied locally to the cervix 1 min before cervical manipulation/dilatation
Study: 16939913
Drug: Cisplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (30 mg/m(2))
Study: 31654485
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable hydrogel contact lenses (etafilcon A)